Education
About Us
Working with TipRanks
Follow Us
TYK Medicines, Inc. Class H (HK:2410)
:2410
2410 Stock Chart & Stats
HK$12.93
-HK$7.80(-21.14%)
At close: 4:00 PM EST
HK$12.93
-HK$7.80(-21.14%)
Day’s Range― - ―
52-Week RangeHK$9.85 - HK$41.40
Previous CloseN/A
Volume117.00K
Average Volume (3M)14.02M
Market Cap
HK$4.23B
Enterprise ValueHK$3.45B
Total Cash (Recent Filing)HK$158.31M
Total Debt (Recent Filing)HK$120.72M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Mar 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding375,457,820
10 Day Avg. Volume4,737,687
30 Day Avg. Volume14,019,805
Financial Highlights & Ratios
PEG Ratio-3.32
Price to Book (P/B)31.87
Price to Sales (P/S)139726.58
P/FCF Ratio-39.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.78
Revenue Forecast (FY)HK$504.00M
Bulls Say, Bears Say
Bulls Say
Improved 2024 CapitalizationPositive shareholders' equity and moderate leverage in 2024 materially improve solvency versus prior years, giving the company more flexibility to fund development programs and survive funding gaps. This stronger capitalization reduces near-term default risk and supports longer-term strategic options.
Substantive Asset BaseA nearly ¥916m asset base provides tangible resources—cash, IP or working assets—that can be deployed for R&D, partnerships, or manufacturing scale. A larger asset cushion supports strategic investments and gives management optionality to pursue long-term growth initiatives or secure financing on better terms.
Positive Gross Profit In 2024Recording positive gross profit indicates the core product or manufacturing economics can cover direct costs. That suggests potential for margin expansion if operating expenses and R&D are controlled and revenue scales, making sustainable profitability achievable at higher volumes.
Bears Say
Persistent Negative Operating Cash FlowConsistent, worsening operating cash burn means the business consumes substantial cash to operate, forcing reliance on external funding. Over months this pressures liquidity, risks dilutive capital raises, and limits the firm's ability to fund R&D or commercialization organically without altering strategy.
Minimal And Volatile RevenueHighly inconsistent, minimal revenues indicate weak product commercialization and uncertain market traction. Without predictable revenue streams, scaling operations and achieving operating leverage is difficult, increasing dependence on financing and making long-term margin improvement uncertain.
Large And Persistent Net LossesSustained substantial net losses erode retained capital and create ongoing pressure to raise funds, diluting shareholders and constraining strategic choices. Long-term recovery requires structural shifts to revenues or cost base; absent that, profitability and returns to investors remain highly uncertain.
TYK Medicines, Inc. Class H News
2410 FAQ
What was TYK Medicines, Inc. Class H’s price range in the past 12 months?
TYK Medicines, Inc. Class H lowest stock price was HK$9.85 and its highest was HK$41.40 in the past 12 months.
What is TYK Medicines, Inc. Class H’s market cap?
TYK Medicines, Inc. Class H’s market cap is HK$4.23B.
When is TYK Medicines, Inc. Class H’s upcoming earnings report date?
TYK Medicines, Inc. Class H’s upcoming earnings report date is Mar 30, 2026 which is in 11 days.
How were TYK Medicines, Inc. Class H’s earnings last quarter?
TYK Medicines, Inc. Class H released its earnings results on Aug 31, 2025. The company reported -HK$0.342 earnings per share for the quarter, beating the consensus estimate of -HK$2.352 by HK$2.009.
Is TYK Medicines, Inc. Class H overvalued?
According to Wall Street analysts TYK Medicines, Inc. Class H’s price is currently Overvalued.
Does TYK Medicines, Inc. Class H pay dividends?
TYK Medicines, Inc. Class H does not currently pay dividends.
What is TYK Medicines, Inc. Class H’s EPS estimate?
TYK Medicines, Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TYK Medicines, Inc. Class H have?
TYK Medicines, Inc. Class H has 375,457,820 shares outstanding.
What happened to TYK Medicines, Inc. Class H’s price movement after its last earnings report?
TYK Medicines, Inc. Class H reported an EPS of -HK$0.342 in its last earnings report, beating expectations of -HK$2.352. Following the earnings report the stock price went up 6.061%.
Which hedge fund is a major shareholder of TYK Medicines, Inc. Class H?
Currently, no hedge funds are holding shares in HK:2410
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TYK Medicines, Inc. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Company Description
TYK Medicines, Inc. Class H
TYK Medicines, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of therapies to address unmet medical needs in cancer treatment. Its lead product candidate is TY-9591, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of brain metastases from non-small cell lung cancer (NSCLC) with EGFR mutations, and in locally advanced or metastatic NSCLC with EGFR L858R mutation. The company also develops TY-302, an oral cyclin-dependent kinase (CDK) 4/6 inhibitor to treat solid tumors, including breast cancer and prostate cancer; TY-2136b, an oral ROS proto-oncogene 1/neurotrophic tyrosine receptor kinase inhibitor for the treatment of solid tumors; TY-2699a, a selective CDK7 inhibitor for the treatment of advanced/metastatic solid tumors; and TY-0540, a selective CDK2/4/6 inhibitor to treat advanced/metastatic solid tumors. In addition, it develops TY-4028, an oral exon 20 insertion-TKI targeting locally advanced or metastatic NSCLC with EGFR exon 20 or HER2 exon 20 insertions; TY-1091, a potent and selective rearranged during transfection proto-oncogene (RET) inhibitor for the treatment of advanced NSCLC with RET gene fusion, advanced medullary thyroid cancer with RET gene mutation, and other advanced solid tumors with RET gene alterations; TY-1054, an oral yes associated protein-transcriptional enhanced associate domain inhibitor for cancer treatment; TY-1210, a selective CDK2 inhibitor to treat solid tumors; TY-0609, a selective CDK4 inhibitor for the treatment of cancer; and TY-3200, an EGFR degrader. The company was incorporated in 2017 and is headquartered in Huzhou, China.
Technical Analysis
Ascletis Pharma, Inc.
―
Jinxin Fertility Group Ltd.
―
HBM Holdings Ltd.
―
Abbisko Cayman Limited
―
China Shineway Pharmaceutical Group Limited
―
Options Prices
Currently, No data available
---